Evaluation of cardio-metabolic effects of Incretin-based therapies in type 2 diabetes
|Professor Sanjoy Paul||Sanjoy.Paul@mh.org.au||+61 3 9342 8772||View page|
Prof. Paul is leading this major research project to evaluate the cardio-metabolic effects of GLP-1 receptor agonists and DPP-4 inhibitors. The initial findings from this study have already gained attention from the international research community with considerable media coverage, and he was invited at international clinical conferences to present the initial findings. The first study on the possible association of treatment with GLP1 RA Exenatide with cardiovascular risk, in comparison to treatment with insulin, has been published in Cardiovascular Diabetology (2576 accesses since published in January 2015).
Prof Sanjoy Paul, Director
Grants from Amylin Pharmaceuticals LLC, and AstraZeneca, USA
Paul SK, Klein K, Maggs D, Best JH. The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study. Cardiovascular Diabetology. 2015;14:10.